Lombardi G, Del Bianco P, Brandes AA, Eoli M, et al. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). Eur J Cancer 2021;155:179-190.
PMID: 34388515